Experienced in Necrotizing Fasciitis

Seiichiro Makihara

Otolaryngology Head And Neck Surgery, 
Okayama, JP 
Experienced in Necrotizing Fasciitis
Otolaryngology Head And Neck Surgery, 
Okayama, JP 
OverviewLocationsClinical Research

Overview

Seiichiro Makihara practices in Okayama, Japan. Makihara is rated as an Experienced expert by MediFind in the treatment of Necrotizing Fasciitis. Their top areas of expertise are Meningocele, Allergic Rhinitis, Sinus Cancer, Endoscopy, and Septoplasty.

Their clinical research consists of co-authoring 61 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Necrotizing Fasciitis.

Locations

Otolaryngology Head And Neck Surgery, Okayama, Japan
Other Locations
Department Of Otolaryngology Head & Neck Surgery, Japan
Department Of Otolaryngology Head And Neck Surgery, Marugame, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomised, Double-blind, Placebo Controlled, Parallel Group Phase III Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) / Eosinophilic Chronic Rhinosinusitis (ECRS) MERIT: Mepolizumab in Eosinophilic Chronic RhinosinusITis Study
A Randomised, Double-blind, Placebo Controlled, Parallel Group Phase III Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) / Eosinophilic Chronic Rhinosinusitis (ECRS) MERIT: Mepolizumab in Eosinophilic Chronic RhinosinusITis Study
Enrollment Status: Completed
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drugs: Mepolizumab, Standard of Care
Study Phase: Phase 3

61 Total Publications

The Intranasal Administration of Semaphorin 3A Inhibitor in a Mouse Model of Olfactory Disorder.
The Intranasal Administration of Semaphorin 3A Inhibitor in a Mouse Model of Olfactory Disorder.
Journal: Cureus
Published: September 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Makihara's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 24 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile